Latest Cdmo News

Page 2 of 2
IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.
Victor Sage
Victor Sage
28 Apr 2026
Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.
Ada Torres
Ada Torres
28 Apr 2026
Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.
Ada Torres
Ada Torres
14 Apr 2026
Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.
Ada Torres
Ada Torres
27 Feb 2026
Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.
Ada Torres
Ada Torres
5 Feb 2026
Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.
Ada Torres
Ada Torres
7 Nov 2025
Epsilon Healthcare Limited reported a $3.25 million loss for 2024, reflecting the financial strain of voluntary administration and efforts to rebuild operations and client confidence.
Ada Torres
Ada Torres
7 Oct 2025
Epsilon Healthcare’s manufacturing arm has secured updated GMP certificates covering domestic and EU/UK markets, reinforcing its quality credentials and paving the way for expanded international contract manufacturing.
Ada Torres
Ada Torres
17 Sept 2025
Epsilon Healthcare has emerged from voluntary administration with a stronger balance sheet, securing refinancing and preparing to launch its new pharmacy platform. Operational stability and strategic initiatives signal a turning point for the healthcare group.
Ada Torres
Ada Torres
28 July 2025
Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.
Victor Sage
Victor Sage
17 Feb 2025
Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.
Ada Torres
Ada Torres
31 Jan 2025

Browse the archive

Full archive